Dr. Stefano R. Tarantolo, MD

Dr. Tarantolo practices at Oncology Hematology West in Omaha, Nebraska.

Dr. Tarantolo's NPI, 1205816667, was assigned on January 20, 2006. Dr. Tarantolo graduated from St. Louis College of Physicians and Surgeons in 1985. Dr. Tarantolo holds Nebraska license 18988.

Dr. Tarantolo's primary practice is Oncology Hematology West, at 17201 Wright St, Omaha, NE 68130 in Douglas County. The practice phone is (402) 354-8124.

Dr. Tarantolo's primary practice is Oncology Hematology West in Omaha, Nebraska. Dr. Tarantolo is also affiliated with Nebraska Medical Center. The medical group on file is Nebraska Cancer Specialists. Dmand AI also links Dr. Tarantolo to 4 more hospitals, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Tarantolo practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Tarantolo's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Tarantolo is licensed in Nebraska.

CMS data shows 212,821 Medicare services from Dr. Tarantolo across 72 procedure codes in 2024, for 973 Medicare patients. Medicare paid $4,227,982 for them.

CMS counts 973 Medicare patients who saw Dr. Tarantolo in 2024. The largest group is 65 to 74, with 428 patients. 75% of them have high blood pressure, and 71% have high cholesterol. 3% are also on Medicaid. Their average risk score is 2.07, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Tarantolo's median patient age at 71, with 50% women.

In 2024, Dr. Tarantolo wrote 3,792 Medicare Part D claims for 333 patients. 77% of them were for generic drugs. CMS names the drug for 3,461 of them, across 55 drugs with 11 or more claims each, at $11,499,710 in total drug cost. In 2023, CMS named 3,098 claims across 51 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Dr. Tarantolo for performance year 2024, reported as part of a group. Dr. Tarantolo accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Tarantolo as offering telehealth.

Dmand AI links 8 papers to Dr. Tarantolo, published from 2011 to 2023. 2012 was the busiest year, with 2. Dr. Tarantolo's most frequent co-authors are Ralph J. Hauke, MD, Subhankar Chakraborty, MD and Surinder K. Batra, MD.

Dmand AI links Dr. Tarantolo to 10 clinical trials, 4 of them phase 2 studies. 6 are still active or recruiting. Conditions studied include Multiple Myeloma, Blood Protein Disorders and Adenocarcinoma Of Esophagus. National Cancer Institute (NCI) sponsors the most, 3.

CMS Open Payments shows 64 general payments to Dr. Tarantolo from 26 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 78% of the total. Sanofi and Genzyme US Companies paid the most, $5,300. It also lists 7 research payments totaling $1,927 from 2018 to 2023.

Dr. Tarantolo graduated from St. Louis College of Physicians and Surgeons in 1985.